Shepherd Veterinary Software vs Biogen
Side-by-side comparison of AI visibility scores, market position, and capabilities
YC-backed cloud veterinary PMS designed from the ground up by veterinarians for modern clinic workflow efficiency. San Francisco CA; founded 2018;
About
Shepherd Veterinary Software is a San Francisco-based cloud veterinary practice management system backed by Y Combinator and designed from the ground up for the operational workflow needs of modern veterinary clinics. Founded in 2018 by veterinarians and technologists who experienced firsthand the frustrations of legacy practice management systems, Shepherd built a clean, intuitive platform that integrates appointment scheduling, medical records, treatment tracking, invoicing, and inventory management into a unified workflow optimized for the pace and multitasking demands of a busy veterinary practice. Unlike older systems that were designed around a desktop paradigm and adapted for web, Shepherd was built as a cloud-native application from day one.\n\nShepherd's clinical workflow design reflects its founding team's veterinary experience. The platform's whiteboard feature provides a real-time view of every patient in the clinic—which exam room they are in, what treatments have been administered, what orders are outstanding, and who is responsible for each task. This "at a glance" operational view reduces the communication overhead between veterinarians, technicians, and receptionists that leads to errors and delays in busy multi-doctor practices. The treatment sheet auto-populates charges based on administered treatments, reducing the billing leakage common in practices where staff must manually add charges from memory.\n\nShepherd targets independent veterinary practices and small veterinary groups in the United States, competing with established systems including IDEXX's AVImark, ezyVet, Cornerstone, and ImproMed in the veterinary practice management market. The company differentiates on user experience quality, cloud-native reliability, and the speed of its development cycle—as a well-funded startup with a modern tech stack, Shepherd can ship product improvements significantly faster than legacy software vendors. Shepherd has gained traction primarily through referrals within veterinary professional networks and targeted digital marketing reaching veterinary clinic owners and practice managers.
Cambridge MA neuroscience biopharma (NASDAQ: BIIB) at $9.7B 2024 revenue; LEQEMBI $87M Q4 (Alzheimer's first-in-class amyloid therapy), SKYCLARYS $102M Q4 (Friedreich's ataxia), MS franchise declining vs. Eli Lilly donanemab.
About
Biogen Inc. is a Cambridge, Massachusetts-based neuroscience biopharmaceutical company — publicly traded on NASDAQ (NASDAQ: BIIB) as an S&P 500 Health Care component — researching, developing, and commercializing therapies for neurological, neurodegenerative, and neurodevelopmental diseases including Alzheimer's disease, multiple sclerosis, spinal muscular atrophy, and rare neurological conditions through approximately 7,400 employees worldwide. In fiscal year 2024, Biogen reported total revenue of $9.7 billion (-2% year-over-year) and GAAP diluted EPS of $11.18 (+40%), reflecting significant cost-cutting that improved profitability despite modest revenue decline. Revenue decline was driven by continued erosion in the core multiple sclerosis franchise (TECFIDERA, AVONEX, TYSABRI facing generic and biosimilar competition) while new product revenue grew: LEQEMBI (lecanemab, Alzheimer's disease, partnered with Eisai) generated approximately $87 million in Q4 2024 global sales — reflecting the slow but building commercial trajectory of the first drug to slow Alzheimer's cognitive decline — and SKYCLARYS (omaveloxolone, Friedreich's ataxia) generated $102 million in Q4, nearly double the year-earlier period. CEO Christopher Viehbacher, who joined in 2022 from Genentech's parent Roche, has led a strategic restructuring that includes cost reduction, pipeline refocus on high-probability neurology programs, and the LEQEMBI commercial execution through a partnership model with Eisai.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.